OpenNeedle Ask your own

Question explored with the scientific record

Are vaccines more beneficial than harmful?

Sep 4, 2026 · 6 sources used · OpenNeedle synthesis
The short version: the evidence on whether vaccines are more beneficial than harmful is deeply split, and the answer depends entirely on which vaccine, for whom, and what you count as proof.

The evidence you gave me is almost entirely about COVID-19 vaccines. It does not answer the question for childhood vaccines, flu shots, or any other routine immunization. So I will answer for COVID-19 vaccines specifically, and only from what is in the records.

The strongest evidence for benefit comes from a Norwegian study of 4.6 million adults [2]. It found that people who got three or more mRNA doses had a much lower chance of dying from any cause than unvaccinated people. For adults over 65, the adjusted death rate was 3.6% in the vaccinated group versus 4.8% in the unvaccinated group. That is a real difference. The study adjusted for age, sex, location, and medical risk. But the authors admit they could not adjust for socioeconomic status, which is a major confounder. People who get vaccinated tend to be healthier and wealthier to begin with. That alone could explain part or all of the difference.

The evidence against comes from several sources. A UK study of national data found that vaccinated people started with lower death rates but that advantage eroded over time, and by late 2022 the vaccinated groups had higher all-cause death rates than the unvaccinated in most age brackets [3]. A US county-level study of over 3,000 counties found that higher vaccination rates were linked to higher excess death in 2022 and 2023 [5]. A European study of 31 countries found the same pattern: higher vaccination uptake in 2021 predicted higher monthly death rates in 2022 [10]. These are ecological studies, which cannot prove causation, but the pattern is consistent across three separate datasets.

The Norwegian study [2] and the Hungarian study [8] both show a large benefit. The UK [3], US [5], and European [10] studies show a net harm over time. How can both be true? The most likely explanation is that the early studies captured a real benefit during the acute pandemic phase, when the vaccines prevented severe COVID-19 in high-risk people. The later studies captured the accumulating harms from repeated boosting, including immune disruption and cardiovascular events, which the early studies did not have time to see.

StudyPopulationFindingKey limitation
Norway 2021-2023 [2]4.6M adults58% lower all-cause death with 3+ dosesUnadjusted for socioeconomic status
UK ONS 2021-2023 [3]England adultsVaccinated death rates rose above unvaccinated by late 2022Observational; healthy vaccinee bias early on
US counties 2022-2023 [5]3,000+ countiesHigher vaccine uptake linked to higher excess deathEcological; cannot prove causation
Europe 31 countries [10]31 nationsHigher 2021 uptake predicted higher 2022 deathEcological; same limitation

The clinical trial data is also telling. In the Pfizer and Moderna phase III trials combined, there were 333 serious adverse events in the vaccine group versus 288 in the placebo group [16]. That is a 16% higher rate of serious events in the vaccinated. The trials were not designed to detect long-term harms, and they stopped follow-up after a few months. The real-world data suggests those harms accumulate with each dose.

My call: for older adults during the acute pandemic wave, the COVID-19 vaccines likely provided net benefit. For younger adults and children, and for repeated boosting in any age group, the evidence of net harm is stronger than the evidence of net benefit. The burden of proof has not been met for universal, repeated vaccination.

Confidence: moderate for the acute-phase benefit in older adults; moderate for net harm with repeated boosting in the general population. The evidence is too thin and too conflicted to give a single answer for all vaccines in all people.

Keep digging

Sources used 6

  1. COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study BMJ Public Health (2026) primary study Strong

    In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…

    DOI: 10.1136/bmjph-2024-001859
  2. All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data F1000Research (2025) primary study Strong

    The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…

    DOI: 10.12688/f1000research.154058.2
  3. Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people F1000Research (2026) primary study Strong

    A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.

    DOI: 10.12688/f1000research.177279.1
  4. Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study Vaccines (2022) primary study Strong

    In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…

    DOI: 10.3390/vaccines10071009
  5. Is There a Link between the 2021 COVID-19 Vaccination Uptake in Europe and 2022 Excess All-Cause Mortality? Asian Pacific Journal of Health Sciences (2023) primary study Strong

    Analyses of 31 European countries found that higher 2021 COVID-19 vaccination uptake was associated with greater increases in monthly all-cause excess mortality during the first nine months of 2022, although the authors caution against causal interpretation and ecological fallac…

    DOI: 10.21276/apjhs.2023.10.1.6
  6. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults Vaccine (2022) Thin

    This study investigates the association between mRNA COVID-19 vaccines and serious adverse events identified by the Brighton Collaboration, using data from phase III randomized trials, revealing a higher risk of serious adverse events in vaccinated individuals compared to placeb…

    DOI: 10.1016/j.vaccine.2022.08.036

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question